# NCI ETCTN Pittsburgh Cancer Consortium (PCC)

> **NIH NIH UM1** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $442,721

## Abstract

Abstract
For more than 40 years, the National Cancer Institute (NCI) has supported an infrastructure 
program to conduct clinical trials across the US. To enhance, facilitate, and expedite the process 
of early-phase drug development, the NCI implemented a comprehensive plan transforming the 
NCI-sponsored early-phase clinical trials program from a series of separate institutions and efforts
to a new, consolidated, integrated program, referred to as the NCI Experimental Therapeutics 
Clinical Trials Network (ETCTN). The UPMC Hillman Cancer Center (formerly the University of 
Pittsburgh Cancer Institute, hereafter referred to as ‘HCC’) has been an NCI-designated 
comprehensive cancer center since 1990, and has been involved in the NCI Early Drug 
Development Program since 1999. Our group was one of 12 academic centers to be selected as 
an ETCTN Lead Academic Organization (LAO) for the phase 1 component, and subsequently 
selected as one of 10 academic centers to integrate phase 2 clinical trial efforts, with responsibility 
for developing, leading, and accruing to ETCTN clinical trials for adult cancer patients. We now 
propose to be a member of the NCI ETCTN as the Pittsburgh Cancer Consortium (PCC) Lead 
Academic Organization in a consortium with the University of Florida Health Cancer Center and 
the Albert Einstein Cancer Center. The goal of the PCC is to create a unified, integrated clinical 
trials network that will allow for more seamless advancement and progress of novel experimental 
agents and/or combinations through early stages of drug development. The eventual goal of our 
program is to greatly facilitate and accelerate the delivery of new cancer therapies to the citizens 
of Pennsylvania, North-Central Florida, Bronx, NY, and their respective catchment areas.

## Key facts

- **NIH application ID:** 10849839
- **Project number:** 5UM1CA186690-08
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** JOHN C. BYRD
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $442,721
- **Award type:** 5
- **Project period:** 2014-03-25 → 2026-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10849839

## Citation

> US National Institutes of Health, RePORTER application 10849839, NCI ETCTN Pittsburgh Cancer Consortium (PCC) (5UM1CA186690-08). Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/grant/nih/10849839. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*